Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan-Feb;12(1):25-32.
doi: 10.1016/j.jacl.2017.11.005. Epub 2017 Nov 22.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data

Steve E Humphries  1 , Jackie Cooper  2 , Peter Dale  3 , Uma Ramaswami  4 ; FH Paediatric Register Steering Group
Affiliations

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data

Steve E Humphries et al. J Clin Lipidol. 2018 Jan-Feb.

Abstract

Background: For children with familial hypercholesterolemia (FH), UK guidelines recommend consideration of statin therapy by age 10 years and dietary and lifestyle advice to maintain an ideal body weight.

Objectives: The objective of the study is to use the UK Paediatric Familial Hypercholesterolemia Register to determine: (1) the prevalence of plasma markers of liver toxicity and muscle damage in statin-treated FH children; (2) the prevalence of obesity in FH children compared to the UK general population; and (3) to compare growth rates in statin-treated and nontreated children.

Methods: Differences in registration and 1-year characteristics were compared by Mann-Whitney U tests. Age and gender body mass index percentiles were compared to UK children's growth charts.

Results: In 300 children (51% boys, 75% Caucasian, untreated mean [standard deviation] low-density lipoprotein cholesterol 5.50 [1.49] mmol/L), the proportion on statins varied significantly (P < .005) by age group (<5 years = 0%, 5-10 years = 16.7%, 10-15 years = 57.1%, and >15 years = 73.2%). Statin treatment reduced low-density lipoprotein cholesterol by 31% (1.84 [1.43] mmol/L), and no child showed elevated levels of markers of liver toxicity or muscle damage. At registration, 16.9% of the FH children were overweight (>85th percentile) and 11.1% were obese (>95th percentile) vs reported in 21.2% in UK non-FH children. There was no difference in annual growth rate in statin vs no-statin groups (age-adjusted weight increases 3.58 vs 3.53 kg; P = .91, height 4.45 vs 4.60 cm P = .73).

Conclusions: We show no evidence for statin-related safety or growth issues, but many FH children over the age of 10 years are not on statin treatment. Fewer UK children with FH are obese compared to UK non-FH children.

Keywords: Familial hypercholesterolemia; LDL-C levels; Obesity; Overweight; Pediatric.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of (A) BMI and (B) age and gender BMI percentile in 243 FH children. (A) 17/243 = 7% had a BMI between 25 and 30 kg/m2 (light stipple bars) and 5/243 = 2.1% had a BMI > 30 kg/m2 (dark stipple bars). (B) 41/243 = 16.9% had an age- and gender-adjusted BMI percentile >85th percentile (light stipple bar) and 27/243 = 11.1% had an age- and gender-adjusted BMI percentile >95th percentile (dark stipple bar). BMI, body mass index; FH, familial hypercholesterolemia.
See this image and copyright information in PMC

Comment in

References

    1. Nordestgaard B.G., Chapman M.J., Humphries S.E. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490a. - PMC - PubMed
    1. Marks D., Thorogood M., Neil H.A., Humphries S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14. - PubMed
    1. Walter K., Min J.L., Huang J. The UK10K project identifies rare variants in health and disease. Nature. 2015;526(7571):82–90. - PMC - PubMed
    1. Wald D.S., Bestwick J.P., Wald N.J. Child-parent familial hypercholesterolemia screening in primary care. N Engl J Med. 2017;376(5):499–500. - PubMed
    1. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37(17):1384–1394. - PubMed

Publication types

Substances